Introduction
Mineralocorticoid receptor antagonists (MRAs) improve morbidity and reduce mortality in heart failure with reduced ejection fraction (HFrEF) with severe symptoms (spironolactone), 1 mild symptoms (eplerenone), 2 and in post-myocardial infarction with systolic dysfunction and/or heart failure (HF) (eplerenone). 3 Mortality rates were reduced by 15-30% and HF readmissions dropped by up to 40% in these landmark trials.
Despite these remarkable improvements in morbidity and mortality, and class IA guideline recommendations, MRAs are still largely underused in routine clinical practice. 4, 5 This may be (at least partly) explained by an undue concern about inducing hyperkalaemia or worsening renal function, 6 -14 and the need for close monitoring of potassium and renal function, 7 but also by a lack of education/promotion about these drugs and their indications.
8 -14 'Real-life' data suggest that non-compliance and discontinuation of therapy is common, especially with regards to MRAs, with less than 50% of daily doses ingested in some series [i.e. a much lower adherence than that reported for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs) and beta-blockers, for example]. 15, 16 Many reports of 'real-life' observational data pointed to a lack of association of MRA therapy with clinical benefit, in contrast with the findings of multiple randomized clinical trials. No matter how extensive are adjustments in statistical analyses, such observation data are usually fraught with residual bias. 17, 18 We hypothesize that one of the major and often overlooked biases is the wrong assumption that patients prescribed MRA therapy at baseline keep their medications unchanged throughout the course of the observation period. Hence, the main goals of the present analysis are to study: (i) the rates and determinants of MRA prescription; (ii) the characteristics of the population with and without MRAs prescribed; (iii) the changes in MRA therapy that occur after baseline observation and during the 9 month period after the baseline observation, and (iv) the determinants of these changes. We took advantage of the European BIOSTAT-CHF programme as a multicentre, multinational, prospective, contemporary, observational study which enrolled patients who had suboptimal dosing or no treatment with ACEi/ARBs and/or beta-blockers, with the aim of optimizing guideline-based use of these agents and examining the predictors of optimization. Patients' characteristics are compared at baseline (Visit 1) and 9 months (Visit 2) of follow-up. This retrospective post hoc analysis was restricted to patients indicated for MRA therapy.
Methods

Patient population
BIOSTAT-CHF is a European project that enrolled 2516 HF patients from 69 centres in 11 European countries to determine profiles of patients with HF that do not respond to recommended therapies, despite anticipated up-titration. The design of the study and patients have been described elsewhere. 19 In brief, patients were aged and/or NT-proBNP plasma levels >400 pg/mL or >2000 pg/mL, respectively. Patients needed to be treated with either oral or intravenous furosemide ≥40 mg/day or equivalent at the time of inclusion. Patients should not have been previously treated with evidence-based therapies (ACEi/ARBs and beta-blockers) or were receiving <50% of the target doses of at least one of these drugs at the time of inclusion. Initiation or up-titration of ACEi/ARB and/or beta-blocker therapy should have been anticipated by the treating physician. The first 3 months of treatment were considered to be the optimization phase, after which a stabilization phase of 6 months was defined. During the optimization phase, initiation or up-titration of ACEi/ARB and/or beta-blocker therapy was performed according to the routine clinical practice of the treating physicians, who were encouraged to follow the European Society of Cardiology (ESC) guidelines at the time of treatment. 20, 21 There were no inclusion criteria nor optimization strategy specific to MRA therapy, which is assumed to be reflective of 'usual care'.
The recruitment period was 24 months, starting from December 2010. The last patient was included on 15 December 2012. Median follow-up was 21 months.
From the original 2516 patients enrolled in the BIOSTAT-CHF programme, the retrospective analysis only included 1325 patients with a formal indication for the use of an MRA [LVEF ≤35%, estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m 2 , and K + ≤5.0 mmol/L] (Figure 1 ).
Statistical analysis
In descriptive analyses, continuous variables are expressed as mean ± standard deviation. Categorical variables are expressed as frequencies and proportions (%). Population description and comparison of patients with MRA vs. without MRA prescribed was performed using independent Student's t-test for normally distributed continuous variables and 2 test for categorical variables. Normality assumptions were verified by visual binning. No multiple imputation was performed.
To determine predictors of having an MRA prescribed (or not) and discontinued (or not), we developed two logistic regression and two multinomial prediction models. Both models used clinical and laboratory variables with a P-value <0.2 as entry criteria. The first model was a forward conditional model eliminating progressively the variables with weaker association and retaining in the final model those variables with a P-value <0.05. The second model used a stepwise backward selection process. Both models provided similar final results. Logistic regression assumptions were checked and multicollinearity excluded. Linear relationship between continuous independent variables and the logit transformation of the dependent variable was verified by plotting the means vs. the estimates in quintiles. If a linear relationship was not present, then the variable was dichotomized at the inflexion point.
The primary outcome was a composite of hospitalization for heart failure (HHF) and all-cause death. Cox proportional hazard regression models were used to model long-term event rate both in univariable and multivariable analysis. Cox model's assumptions were verified. An interaction term between the variable of interest (MRA) and time was tested within the Cox model. In the multivariable models, the covariates for adjustment were chosen from demographic (age and gender), clinical [body mass index (BMI), LVEF, European region, congestion signs and symptoms, coronary revascularization, hypertension history, diabetes, medication, and systolic blood pressure (SBP)], and laboratory (eGFR determined by the CKD-EPI formula 22 and haemoglobin). All parameters were previously found to be independently associated with the outcome of HHF or all-cause death in the BIOSTAT-CHF cohort. These variables were also used to create a propensity score (PS) from a logistic regression model. The PS and its logit were also used for adjustment as covariates providing similar results 23 (data not shown).
The European region was divided into southern countries (Greece, Italy, Serbia, Slovenia, and France) vs. northern countries (Netherlands, Sweden, Norway, Germany, Poland, and UK).
The adjudication of events (HHFs) were done by the treating physician.
All analyses were performed with SAS ® software version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of the study population
At baseline, MRAs were prescribed in 741 (56%) patients. Characteristics of the patients according to MRA prescription at baseline and changes in MRA prescription between baseline and 9 months are presented in Table 1 . Patients with MRA prescription at baseline were younger, more often male, had higher BMI, higher potassium levels, lower SBP, lower NT-proBNP, were more often from Southern Europe, had worse NYHA class, had more often a cardiac device, more coronary interventions, were more often hospitalized for worsening HF in the year before the baseline visit, had ACEi/ARBs prescribed more frequently but achieved ≥50% target dose of such therapies less frequently, had beta-blockers prescribed more frequently but also achieved ≥50% target dose . of beta-blockers less frequently; they also had digoxin prescribed more frequently (P < 0.05 for all). As compared with patients without any MRA prescription, patients in which an MRA was prescribed both at baseline and 9 months were younger, were more often from Southern Europe (but Southern Europe patients were also the ones who had a higher proportion of MRA discontinuation at some point between baseline and 9 months), had lower heart rate, lower SBP, higher serum potassium levels, had more often hypertension history, and a loop diuretic prescribed (P < 0.05 for all) ( Table 1) .
Characterization of patients with and without mineralocorticoid receptor antagonist at baseline
At baseline, MRA recipients had greater odds of having a higher BMI, being from Southern Europe, having a worse NYHA class, having been hospitalized for worsening HF in the year before the baseline visit, having a device implanted, and having a hypertension history. Patients not receiving MRA therapy had higher odds of being older, having higher blood pressure, and having hypokalaemia ( Table 2 ).
Factors associated with mineralocorticoid receptor antagonist therapy change up to 9 months during the post-discharge period
From the 1325 patients present at baseline, 276 (21%) were lost to follow-up, from which 169 (61%) died, and 107 (39%) patients did not complete the 9 month visit (data missing). Characteristics of these 276 compared with the remaining 1049 patients are depicted in Table S1 in the Supplementary material online.
Of the 1049 patients who completed both baseline and 9 month visit, an MRA was prescribed at baseline in 585 (56%) patients and at 9 months in 662 (63%) patients. Among the 585 patients with an MRA prescription at baseline, 91 (16%) had discontinued therapy and among the 461 (44%) patients without MRA prescription at baseline, 168 (36%) had initiated therapy subsequently ( Table 3 and Figure 2 ). When looking at the specific drug, 448 (42.8%) of the patients were taking spironolactone and 137 (13.1%) eplerenone. The proportion of patients who discontinued spironolactone and eplerenone was similar (15% and 17.5%, respectively), whereas the majority of patients who initiated MRA during the 9 month follow-up were started on spironolactone (23.9% vs. 12.6%) (Table S2 in the Supplementary material online).
Factors associated with MRA discontinuation were a higher LVEF and worse NYHA class. Having a higher heart rate, SBP ≥140 mmHg and K + <4 mmol/L at baseline was associated with MRA initiation between baseline and 9 months, whereas patients from Southern Europe were less likely to initiate an MRA between baseline and 9 months ( Table 4) . Of the 1049 patients who completed the two visits, 578 (55%) had an echocardiography performed at both visits (45% missing values). Of these 578 65.7 ± 12.4
64.6 ± 12.4
68.9 ± 12.0
<0.001
Male gender, n (%) 
Potassium <4 mmol/L, n (%) 
Outcome associations
MRA prescription both at baseline and 9 months was not associated with lower primary outcome event rates as compared with receptor antagonists (MRAs) prescribed in the two study visits relative to the total (n = 1049) of the patients who completed the two study visits, and changes in MRA prescription between baseline and 9 months. Total = 1046 patients due to three (0.3%) missing values.
not having an MRA prescription [adjusted hazard ratio (HR) 1.02, 95% confidence interval (CI) 0.66-1.58, P = 0.93]. MRA prescribed only at baseline was associated with dismal outcomes in unadjusted models but not after adjustment (unadjusted HR 1.80, 95% CI 1.07-3.05, P = 0.028 and adjusted HR 1.68, 95% CI 0.92-3.07, P = 0.092). MRA prescription only at 9 months was also not associated with the primary outcome of mortality or HHF (adjusted HR 1.50, 95% CI 0.89-2.53, P = 0.13) ( Table 5 ).
Discussion
Our study based on a symptomatic HFrEF population with suboptimal ACEi/ARB and/or beta-blocker therapy showed that MRAs were largely under-prescribed and frequently changed (i.e. discontinued or initiated) in a short follow-up of 9 months. In this population, only ∼56% of patients with HFrEF with a formal indication for MRA treatment were actually receiving an MRA and within 9 months more than 15% of patients receiving an MRA discontinued, while another 36% without MRA at baseline initiated. We identified common features and determinants for MRA prescription and discontinuation. To the best of our knowledge, this is the first report on treatment initiation and cessation in only a 9 month time period. It is, therefore, very difficult to categorize patients in observational studies in MRA vs. non-MRA, since receiving MRA therapy is a highly unstable condition and moving target. Consequently, reports of observational data, emphasizing lack of association of MRA therapy with clinical benefit, are in contrast with the findings of multiple randomized clinical trials. These reports are usually fraught with residual biases but are also critically invalidated because all are based on the wrong assumption that patients prescribed MRA therapy at baseline keep their medications unchanged throughout the course of the observation periods.
17,18
Previous observational reports confirmed that MRAs are under-prescribed. In the Get With The Guidelines-HF quality improvement registry, 4 A backward was performed according to the type 3 analyses effect (global effect). Country locations in the BIOSTAT-CHF were considered as follows. Southern Europe: Greece, Italy, France, Serbia, and Slovenia; Northern Europe: Netherlands, Sweden, Norway, Germany, Poland, and UK. BMI, body mass index; CABG, coronary artery bypass grafting; CI, confidence interval; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.
the corresponding prescription, that varied widely across United States (US) regions and clinicians. In that registry, MRA prescription was also less common among elderly patients, those who have worse renal function, and those with lower blood pressure. In our study, patients with higher and improved LVEF and worse NYHA class were more likely to have MRAs discontinued between baseline and 9 months. Interestingly, patients with hypertension history more often received MRA therapy, whereas patients not receiving MRAs had more often SBP ≥140 mmHg and hypokalaemia, which is consistent with the anti-hypertensive and potassium-sparing effects of MRA therapy. 24 More frequent use of MRA therapy in patients with highest BMIs suggests that clinicians may intuitively perceive that MRA therapy is more effective in overweight patients. Actually, experimental and clinical data suggest that this may be the case. 25 Interestingly, we have also recently reported data from the Eplerenone for Heart Failure with Mild Symptoms (EMPHASIS-HF) trial suggesting that patients with abdominal obesity derive the largest benefit from eplerenone therapy. The 1049 patients who completed the two study visits were included in the analysis. Time was set from 9 months until the end of the study and events previous to 9 months were censored. CI, confidence interval; HR, hazard ratio; MRA, mineralocorticoid receptor antagonist. a Adjusted on the clinical model derived from the BIOSTAT-CHF dataset that includes age, heart failure hospitalization in the last year, peripheral oedema, systolic blood pressure, estimated glomerular filtration rate, urea, NT-proBNP, haemoglobin, sodium, and use of beta-blocker agent at baseline.
26,27
The EURObservational Research Programme: Heart Failure Pilot Survey (ESC-HF Pilot) enrolled 5118 patients admitted for acute HF from 136 cardiology centres in 12 European countries in 2009-10. In this survey, the rate of MRA therapy at hospital discharge was ∼25% prior to hospitalization and ∼50% after hospitalization. 28 The use of MRAs in the US is even lower than in Europe. 29, 30 Our data suggest that MRA use in the periods between 2009 and 2010 did not improve much up to 2010-12, with only about half of the patients with compelling indication actually receiving the drug. In the 2008 ESC HF guidelines it is stated that 'aldosterone antagonists should be considered in all patients with a LVEF ≤35% and severely symptomatic HF', 21 hence most patients included in our study had formal indication for MRAs. It should be noticed that the results of the EMPHASIS-HF trial 2 expanding the recommendation of use of MRA therapy to all symptomatic HFrEF patients was only integrated in the 2012 ESC guidelines 20 and subsequently in the 2016 ESC guidelines. 31 Despite guideline indication, other factors may be responsible for the persistently low prescription rate, and these include the excessive concern raised by the publication of population-based studies associating MRA therapy with the increase in hyperkalaemia-associated morbidity and mortality. 32, 33 As subsequently recognized, patients enrolled in these studies commonly received inappropriate dosing, or had formal contraindications to MRA therapy, and had below trial-and guideline-recommended serum potassium and renal function monitoring. 34 -36 It is also noticeable that there is a poor understanding of the mechanisms of action of MRAs beyond their 'diuretic with potassium-sparing properties' heading, 37 lack of pharmaceutical company-sponsored drug marketing and education for clinicians, 4 and lack of guidance on how to initiate MRAs on a background of ACEi/ARBs and beta-blocker up-titration. 13, 38 The educational gap must be recognized and specifically addressed. Spironolactone is a generic drug, orphaned from any industry promotional or educational support. Eplerenone is hardly supported by its single sponsor because of the quick loss of patent shortly after its market launch.
In our study, a high rate (more than 15%) of MRA discontinuation during a short period of follow-up (∼9 months) was observed. However, an even higher rate of MRA initiation (in patients without baseline MRA prescription) was observed (36%) programme. Patients at the highest end of the guidelinerecommended HFrEF range (<35%) or with LVEF improvement above 35%, and with worse NYHA class were more likely to have MRA treatment discontinued. Moreover, being older was associated with having no MRA prescribed at all. Our data do not provide granularity on why patients have stopped the drug, but they may suggest that clinicians' perception of patients' status is likely to play a role in these decisions and is a potential target for intervention. 39 Patient compliance cannot be assessed from our data, and compliance with treatments is a major issue, 40 especially concerning MRAs. 41, 42 Notwithstanding, we may observe that potassium levels were higher in the group of patients with MRA prescription, which is an indirect sign of treatment adherence.
Clinical and research implications
Our findings, together with other previous observations of underuse and under-dosing of MRA therapy should prompt a vigorous call to action. So many reports have consistently emphasized the lack of adherence with the highest evidence-based strongly recommended life-saving MRA therapy in HFrEF, with little proactive action taken, especially in Europe. At least in the US, the Get With The Guidelines initiative is aiming at mitigating the general issue of poor adherence to guidelines, with encouraging results. 5 Actions directed towards clinical education and training (not only in the field of Cardiology, but also Internal Medicine, Geriatrics, Emergency Medicine, Nephrology, Endocrinology, etc.) should be applied in order to improve the use of MRA therapy, but also to instruct on how to make the best use of it. The main reason for underuse, under-dosing or frequent discontinuation and no re-initiation of MRAs is the excessive concern about the risk of worsening renal function and of hyperkalaemia.
9,43 -46 Although, it has been consistently reported that despite occasional decline in eGFR and rise in potassium after initiating or up-titrating an MRA, patients do benefit from life-saving MRA therapy. 43 It also appears that in clinical practice, the rate of monitoring of renal function and serum potassium is suboptimal, and below guideline recommendation. 36 Therefore, emphasizing that both decline in eGFR and rise in potassium are predictable, frequently transient and reversible, and also manageable, is an important part of education about optimal guideline implementation and disease management programmes. Regarding the new potassium binders, 4, 7, 40 rather than increasing the undue concern about hyperkalaemia as a consequence of marketing-based medicine, we should encourage generating appropriate trials evidence that these may indeed improve the use of MRA therapy and consequently maximize clinical benefit. More frequent and guideline-based potassium and renal function monitoring should also be emphasized, given the very low rate of such monitoring associated with the use of MRA in daily practice. 47 Improvement in health care systems and 'HF programmes' such as nurse-led HF care, should be widely implemented since they increase adherence to therapy and improve outcomes while reducing overall costs. 48 -50 From a research perspective, the development of point of care home self-monitoring of serum potassium and renal function, together with other congestion assessments, backed by electronic algorithms, and other prescription-helping tools may improve quality of care provision while monitoring performance measures.
Future reports of observational data should take into account the prescription changes during the observation period, and these MRA prescription alterations should be included in the analysis in a time-dependent manner in order to mitigate treatment allocation bias and to provide a closer picture of 'real-world' clinical practice.
Limitations
Several limitations should be noticed in this study. First, this is a secondary analysis of a prospective non-randomized observational study, therefore all limitations inherent to such analysis are applied herein, including the inability to infer causality (for example, we cannot know if patients with worse NYHA class were more likely to have MRA discontinued because they were 'sicker' or if they were more symptomatic because they did not have MRA prescribed). Second, this study was not designed to address MRA prescription with sufficient granularity, hence these data do not allow the assessment of treatment doses or MRA prescription before baseline visit nor the exact timing of when the medication was stopped or initiated. Third, patient selection for the BIOSTAT-CHF study was based on under-prescription of ACEi and beta-blockers, therefore MRA under-prescription possibly does not reflect 'real life' completely. On the other hand, the MRA prescription increase observed between visits may represent an overestimation of 'real-world' practice, as doctors participating in the BIOSTAT-CHF programme were clearly instructed to up-titrate HF treatments, hence limiting the generalizability of the results and external validity. Third, the reason(s) why patients have discontinued MRAs are not depicted in the dataset. Medication registry was mandatory at each visit but the reason why a medication was discontinued was not registered. Therefore, we cannot know how many patients discontinued MRA due to hyperkalaemia, worsening renal function, or gynaecomastia, for example. Lastly, it was not possible to determine the association of MRA use with outcome due to high rates of discontinuation/initiation during follow-up. This may be turned into a strength of this manuscript, demonstrating that all 'real-life' outcome associations (particularly with MRAs) are prone to this type of bias and are therefore potentially misleading.
. 
Conclusion
In this multicentre international European cohort, MRAs were largely under-prescribed and frequently discontinued. Only slightly more than half of the patients with indication for MRA therapy received it and more that 15% of patients discontinued therapy in the few months following the baseline visit, while another 36% of patients without MRA prescription at baseline initiated it, reflecting the 'up-titration' guidance of the BIOSTAT-CHF programme. We identified determinants of prescription and therapy discontinuation and we suggest actionable measures to improve prescription and adherence. Given the frequent dynamic changes in therapy, we strongly warn against the use of observational data to infer about association between MRA use at a certain time point and subsequent outcome.
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